Clinical Trials Browser

Bile Duct Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Biliary Tract Neoplasms

Genital Neoplasms, Male

Gallbladder Cancer Unresectable

Pancreatic Neoplasms

Adenocarcinoma, Pancreatic Neoplasms

Nasopharyngeal Carcinoma

Pancreatic Neoplasms

Nasopharyngeal Carcinoma

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Urinary Bladder Neoplasms

Biliary Tract Neoplasms

Cholangiocarcinoma

Leiomyosarcoma, Neoplasm Metastasis, Sarcoma

Borderline Resectable Pancreatic Adenocarcinoma

Pancreatic Neoplasms

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Pancreatic Cystic Neoplasm

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Lymphoma, Extranodal NK-T-Cell

Lung Diseases, Interstitial

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Resectable Pancreatic Cancer

Cholangiocarcinoma

Bile Duct Neoplasms, Cholangiocarcinoma

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Carcinoma, Non-Small-Cell Lung

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Liver Neoplasms

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease, Recurrence

Pancreatic Neoplasms

Recurrence, Lymphoma, Large B-Cell, Diffuse

Cholangiocarcinoma

Phase 2 Study

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Triple Negative Breast Neoplasms

Infiltrating Bladder Urothelial Carcinoma

Biliary Tract Neoplasms

Neoplasm Metastasis

Pancreatic Adenocarcinoma

Clinical Trials

Ablatio

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

LIGHT

REVIVE

GENE

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

GCND

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

NABPLAGEMD

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

DOVE

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

TARSARC

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

ZN-c3 + Gemcitabine in Pancreatic Cancer

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

ERASE-Chemo

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

ToPCourT

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

ORIGIN2

Study of Lacutamab in Peripheral T-cell Lymphoma

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

SWITCH

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma